DGAP-News

Avagenesis Corp. Receives ISO 13485 and 9001 for Bioprocessing and Cell Isolation System

DGAP-News: Avagenesis Corp. / Key word(s): Miscellaneous
Avagenesis Corp. Receives ISO 13485 and 9001 for Bioprocessing and
Cell Isolation System

03.09.2015 / 20:54

---------------------------------------------------------------------


Calgary, Alberta--(Newsfile Corp. - September 3, 2015) - Avagenesis Corp.
(TSXV: VVA) ('Avagenesis' or the 'Company') is pleased to announce that its
licensed bioprocessing and cell isolation system has received a Certificate
of Registration for compliance with ISO 13485 and 9001 (the 'ISO
Certification').

ISO Certification demonstrates to customers that the Company's contracted
commercially manufactured bioprocessing system to isolate stem cells and
regenerative cells from adipose liposuction fat has been certified to
applicable standards with rigorous quality assurance and is a quality
product for global markets and leading researchers.

ISO 13485:2003 harmonizes medical device regulatory requirements for
quality management systems. It demonstrates a company's ability to provide
medical devices and related services that consistently meet customer and
regulatory requirements.

ISO 9001:2008 is a quality management system that consistently meets
customer and applicable statutory and regulatory requirements. It aims to
enhance customer satisfaction through the effective application of the
system, including processes for continual improvement of the system and the
assurance of conformity to customer and applicable statutory and regulatory
requirements.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of
medical technologies for use in the practice of cosmetic surgery and
regenerative medical aesthetics. Avagenesis' development activities are
focused on the complex task of efficiently isolating high quality, viable
and potent adipose-derived adult stem cells and regenerative cells using
patent-pending and patented bioprocessing and cell isolation technology.
For licensing and strategic reasons, all patent registrations, FDA
registrations and other regulatory certificates are arranged through an
exclusive licensing agreement with a related and affiliated company.

Neither the Exchange nor its regulation services provider (as that term is
defined in the policies of the Exchange) accepts responsibility for the
adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future events or